EMA's New Vaccine Confidence Panel Signals Tighter Benefit-Risk Communication Expectations

The European Medicines Agency has established a formal advisory group on vaccine confidence, a structural move that signals evolving expectations around benefit-risk communication and science outreach obligations for vaccine manufacturers operating in the EU. The group convened for the first time on 29 April 2026 and will meet quarterly, embedding vaccine hesitancy analysis into EMA's ongoing regulatory posture rather than treating it as a peripheral concern.

The panel comprises more than 20 European and international experts drawn from academia, healthcare professional bodies, medical societies, patient organisations, and public health institutions. Its remit spans four core functions:

• Advising on environmental analysis of vaccine hesitancy trends
• Contributing to EMA's ongoing vaccine confidence initiatives
• Improving public benefit-risk communication on vaccines
• Amplifying the Agency's science outreach and public health messaging

Meeting summaries will be published following each session, creating a traceable record of advisory outputs that regulatory affairs teams should monitor for emerging guidance signals.

The advisory group sits within EMA's broader Vaccine Outreach Strategy, which is designed to increase public and healthcare professional knowledge of vaccine quality, safety, and effectiveness. Practical outputs already under the strategy include scientific communications developed jointly with EU medical academies and a collaboration with the European Academy of Paediatrics on Vaccine Essentials, a tool to support vaccine literacy. The advisory group will guide further editions of that resource. EMA also participates in campaigns such as European Immunisation Week and maintains a public-facing repository addressing vaccine-related concerns and misinformation.

For QA directors and regulatory affairs leads, the formation of this group warrants attention in post-market surveillance planning. As EMA formalises its approach to monitoring and responding to vaccine hesitancy, manufacturers should anticipate that benefit-risk communication frameworks and post-authorisation commitments may be subject to increased scrutiny. Composition and terms of reference for the advisory group are published on the EMA website.